Seaport Therapeutics (SPTX)

Currency in USD
24.40
+0.18(+0.74%)
Closed·
24.400.00(0.00%)
·
Trading near 52-week High
SPTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
23.5225.07
52 wk Range
14.8525.07
Key Statistics
Prev. Close
24.4
Open
24.41
Day's Range
23.52-25.07
52 wk Range
14.85-25.07
Volume
98.61K
Average Volume (3m)
175.64K
1-Year Change
-
Book Value / Share
7.89
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SPTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
38.00
Upside
+55.74%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

Seaport Therapeutics News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 38.00
(+55.74% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
JPMorgan
Buy44.00+80.33%45.00MaintainAug 05, 2026
H.C. Wainwright
Buy50.00+104.92%-MaintainAug 04, 2026
H.C. Wainwright
Buy50.00+104.92%-New CoverageJul 15, 2026
Stifel
Buy30.00+22.95%-MaintainJun 09, 2026

Earnings

Latest Release
Aug 03, 2026
EPS / Forecast
-1.78 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

SPTX Income Statement

Compare SPTX to Peers and Sector

Metrics to compare
SPTX
Peers
Sector
Relationship
P/E Ratio
−9.7x−2.5x−0.3x
PEG Ratio
-−0.110.00
Price/Book
3.1x1.6x2.6x
Price / LTM Sales
-2.3x3.1x
Upside (Analyst Target)
42.8%93.0%49.0%
Fair Value Upside
Unlock5.5%6.3%Unlock

Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company’s lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. Its second product candidate, GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder in Australia and major depressive disorder in Australia and the European Union. The company was founded in 2024 and is based in Boston, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
8.67M16.20%211.65M
Other Institutional Investors
34.26M64.01%836.05M
Public Companies & Retail Investors
10.59M19.79%258.44M
Total
53.53M100.00%1.31B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
PureTech Health plc31.17%16,685,013407,114
ARCH Venture Fund XII, L.P.11.76%6,294,951153,597

People Also Watch

53.59
COAG
-2.46%
38.25
AVLN
-2.55%
18.51
KLRA
+3.18%
25.03
YSWY
-0.56%
6.65
SUJA
+2.62%

FAQ

What Is the Seaport Therapeutics (SPTX) Stock Price Today?

The Seaport Therapeutics stock price today is 24.40 USD.

What Stock Exchange Does Seaport Therapeutics Trade On?

Seaport Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Seaport Therapeutics?

The stock symbol for Seaport Therapeutics is "SPTX."

What Is the Seaport Therapeutics Market Cap?

As of today, Seaport Therapeutics market cap is 1.31B USD.

What Is Seaport Therapeutics's Earnings Per Share (TTM)?

The Seaport Therapeutics EPS (TTM) is -8.50.

When Is the Next Seaport Therapeutics Earnings Date?

Seaport Therapeutics will release its next earnings report on Aug 03, 2026.

From a Technical Analysis Perspective, Is SPTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Seaport Therapeutics Stock Split?

Seaport Therapeutics has split 0 times.

How Many Employees Does Seaport Therapeutics Have?

Seaport Therapeutics has 58 employees.

What is the current trading status of Seaport Therapeutics (SPTX)?

As of Aug 18, 2026, Seaport Therapeutics (SPTX) is trading at a price of 24.40 USD, with a previous close of 24.40 USD. The stock has fluctuated within a day range of 23.52 USD to 25.07 USD, while its 52-week range spans from 14.85 USD to 25.07 USD.

What Is Seaport Therapeutics (SPTX) Price Target According to Analysts?

The average 12-month price target for Seaport Therapeutics is 38.00 USD, with a high estimate of 50 USD and a low estimate of 30 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +55.74% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.